Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Viking Therapeutics Inc’s stock clocked out at $34.26, down -0.03% from its previous closing price of $34.27. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 2.84 million shares were traded. VKTX stock price reached its highest trading level at $34.93 during the session, while it also had its lowest trading level at $32.9.
Ratios:
To gain a deeper understanding of VKTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.34 and its Current Ratio is at 28.34. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 29, 2025, initiated with a Buy rating and assigned the stock a target price of $106.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $104.
On April 08, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $30.Goldman initiated its Neutral rating on April 08, 2025, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 28 ’25 when Mancini Marianna sold 6,185 shares for $35.00 per share. The transaction valued at 216,492 led to the insider holds 382,467 shares of the business.
Rowland Charles A Jr sold 60,000 shares of VKTX for $2,134,278 on Oct 27 ’25. The Director now owns 30,000 shares after completing the transaction at $35.57 per share. On Oct 28 ’25, another insider, Lian Brian, who serves as the President & CEO of the company, sold 38,989 shares for $35.01 each. As a result, the insider received 1,364,923 and left with 2,419,109 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 3872624896 and an Enterprise Value of 3158810112.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.70, which has changed by -0.34102714 over the last 52 weeks, in comparison to a change of 0.1028198 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $56.25, while it has fallen to a 52-week low of $18.92. The 50-Day Moving Average of the stock is 5.05%, while the 200-Day Moving Average is calculated to be 15.91%.
Shares Statistics:
It appears that VKTX traded 5.18M shares on average per day over the past three months and 4091410 shares per day over the past ten days. A total of 112.45M shares are outstanding, with a floating share count of 109.84M. Insiders hold about 3.00% of the company’s shares, while institutions hold 65.27% stake in the company. Shares short for VKTX as of 1761868800 were 24173606 with a Short Ratio of 4.66, compared to 1759190400 on 27543130. Therefore, it implies a Short% of Shares Outstanding of 24173606 and a Short% of Float of 25.629999999999995.
Earnings Estimates
Viking Therapeutics Inc (VKTX) is presently subject to a detailed evaluation by 14.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.76 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$2.07 and -$2.87 for the fiscal current year, implying an average EPS of -$2.57. EPS for the following year is -$3.66, with 13.0 analysts recommending between -$3.13 and -$4.83.
